1.1 This practice is for the quantitative determination of the crystalline phase content of calcium phosphate, calcium sulphate, and calcium carbonate bioceramics by Rietveld refinement of powder X-ray diffraction (XRD) data . 1.2 Calcium salts used for biomedical application may contain amorphous or poorly crystalline phases. Whether or not identification and quantification of a specimen is possible depends on the crystallinity, the presence of amorphous phases, and the amount of peak-overlap among the crystalline phases. It is the responsibility of the user of this practice to decide whether a refinement is stable and trustworthy. This document provides guidelines as to how to judge the quality of the refinement, but it does not attempt to define hard limits for a successful quantification. 1.3 Structural models for most common calcium salts are suggested in this practice. Models for additional phases shall be taken from high-quality single-crystal XRD data. A reference to the source of the model shall be provided. 1.4 This practice requires the use of monochromated and/or Ni-filtered CuK radiation. 1.5 Include in this section the system of units to be used. Refer to the above ASTM Standards Units toolbar button for a dropdown menu of ASTMs Form and Style Manual statements. 1.6 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.
new extended standard practice applicable for all bone substitute material as compared to F2024
KeywordsXRD, Rietveld, Calcium phosphate, calcium sulphate, calcium carbonate
The title and scope are in draft form and are under development within this ASTM Committee.Back to Top
Draft Under Development